A clinical trial evaluating IMX-110 in pediatric patients with rhabdomyosarcoma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jun 2023 According to an Immix Media Release, the company announced that it has completed its previously announced at-the market equity offering program. It has completed 5 million dollars common stock offering. It intends to use net proceeds from the ATM offering for its IMX-110 plus tislelizumab phase 1b combination clinical trial, its IMX-110 monotherapy clinical trial and general corporate purposes.
21 Nov 2022 New trial record
11 Nov 2022 According to Immix Biopharma media release, company has received Institutional Review Board (IRB) approval to enroll pediatric patients in this trial. Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com